BioSpace News Archive

DENTSPLY SIRONA Inc., The Dental Solutions Company™, announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share of common stock, an indicated annual rate of $0.40 per share.

The sudden outbreak of the COVID-19 virus made the 2020 Chinese New Year one of the most unusual ever.

Second Generation Practice of Dr. Michael Barnes, D.D.S., in Newport Beach takes the Crown for February.

Feb. 28, 2020 11:05 UTC Transformative Initiative Expected to Accelerate Development of CH5126766 (VS-6766), a RAF/MEK Inhibitor, in Combination with Defactinib, a FAK Inhibitor, for the Treatment of KRAS Mutant Solid Tumors Company Continues to Advance Development of Duvelisib for the Treatment of Relapsed/Refractory PTCL Strengthened Balance Sheet Through Private Placement Resulting in Anticipated Gross Proceeds of $100 Million; Projected Cash Runway into 4Q 2021

Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the fourth quarter and full year ended December 31, 2019

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 6, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2019 and to provide a business overview.

The Van Drunen Family of Companies (“VDF | FutureCeuticals”) and Folium Biosciences (“Folium”) today announced a new strategic partnership whereby sister companies Van Drunen Farms and FutureCeuticals will be the exclusive distributor in the food, beverage and supplements category for Folium products around the world.

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, “Engine”), which owns approximately 5.5% of the Company’s outstanding shares, pursuant to which Alan L. Bazaar will immediately join PDL’s Board of Directors as a Class III director serving until the Company’s 2022 Annual Meeting of Stockholders.

Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.

Agilent Technologies Inc. announced the following webcasts for the investment community.